Artículo
Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation
Autor/es | Rey, E.
Ampuero Herrojo, Javier Molina-Jiménez, F. García-García, Y. Muñoz Hernández, Rocío Romero Gómez, Manuel García-Monzón, C. Majano, P. González-Rodríguez, A. |
Departamento | Universidad de Sevilla. Departamento de Medicina |
Fecha de publicación | 2021-01-12 |
Fecha de depósito | 2022-11-09 |
Publicado en |
|
Resumen | In the present study, we have demonstrated that sofos buvir (SOF) treatment improves systemic insulin resis tance in hepatitis C virus (HCV)-patients, and, for the first
time, revealed which molecular mechanisms are ... In the present study, we have demonstrated that sofos buvir (SOF) treatment improves systemic insulin resis tance in hepatitis C virus (HCV)-patients, and, for the first time, revealed which molecular mechanisms are involved in SOF effects on the impaired insulin response induced by HCV in hepatocytes. |
Agencias financiadoras | Instituto de Salud Carlos III European Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER) |
Identificador del proyecto | PI16/00823
PI17/0535 PI17/0008 |
Cita | Rey, E., Ampuero Herrojo, J., Molina-Jiménez, F., García-García, Y., Muñoz Hernández, R., Romero Gómez, M.,...,González-Rodríguez, A. (2021). Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation. Clinical and translational medicine, 11 (1), e275. https://doi.org/10.1002/ctm2.275. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Sofosbuvir...pdf | 1.688Mb | [PDF] | Ver/ | |